JP5730433B2 - シート状細胞培養物の製造方法 - Google Patents
シート状細胞培養物の製造方法 Download PDFInfo
- Publication number
- JP5730433B2 JP5730433B2 JP2014208847A JP2014208847A JP5730433B2 JP 5730433 B2 JP5730433 B2 JP 5730433B2 JP 2014208847 A JP2014208847 A JP 2014208847A JP 2014208847 A JP2014208847 A JP 2014208847A JP 5730433 B2 JP5730433 B2 JP 5730433B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- sheet
- cell culture
- culture
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004113 cell culture Methods 0.000 title claims description 172
- 238000004519 manufacturing process Methods 0.000 title claims description 55
- 210000004027 cell Anatomy 0.000 claims description 260
- 238000000034 method Methods 0.000 claims description 88
- 210000002966 serum Anatomy 0.000 claims description 83
- 210000001519 tissue Anatomy 0.000 claims description 50
- 239000000758 substrate Substances 0.000 claims description 41
- 238000010257 thawing Methods 0.000 claims description 35
- 238000007710 freezing Methods 0.000 claims description 32
- 230000008014 freezing Effects 0.000 claims description 32
- 201000010099 disease Diseases 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 108090000695 Cytokines Proteins 0.000 claims description 28
- 102000004127 Cytokines Human genes 0.000 claims description 27
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 19
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 18
- 210000004683 skeletal myoblast Anatomy 0.000 claims description 16
- 238000005406 washing Methods 0.000 claims description 15
- 239000006143 cell culture medium Substances 0.000 claims description 12
- 239000002577 cryoprotective agent Substances 0.000 claims description 12
- 230000005856 abnormality Effects 0.000 claims description 8
- 210000002027 skeletal muscle Anatomy 0.000 claims description 5
- 210000004087 cornea Anatomy 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- 208000018035 Dental disease Diseases 0.000 claims description 3
- 208000012659 Joint disease Diseases 0.000 claims description 3
- 208000016222 Pancreatic disease Diseases 0.000 claims description 3
- 208000017442 Retinal disease Diseases 0.000 claims description 3
- 208000014151 Stomatognathic disease Diseases 0.000 claims description 3
- 208000024799 Thyroid disease Diseases 0.000 claims description 3
- 210000000845 cartilage Anatomy 0.000 claims description 3
- 208000015100 cartilage disease Diseases 0.000 claims description 3
- 208000021921 corneal disease Diseases 0.000 claims description 3
- 210000000959 ear middle Anatomy 0.000 claims description 3
- 208000028299 esophageal disease Diseases 0.000 claims description 3
- 210000003238 esophagus Anatomy 0.000 claims description 3
- 210000004195 gingiva Anatomy 0.000 claims description 3
- 208000019622 heart disease Diseases 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 208000022949 middle ear disease Diseases 0.000 claims description 3
- 210000004165 myocardium Anatomy 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 210000001525 retina Anatomy 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 3
- 208000029578 Muscle disease Diseases 0.000 claims description 2
- 208000021510 thyroid gland disease Diseases 0.000 claims description 2
- 239000002609 medium Substances 0.000 description 45
- 239000000243 solution Substances 0.000 description 45
- 239000000306 component Substances 0.000 description 32
- 230000000694 effects Effects 0.000 description 32
- 239000003102 growth factor Substances 0.000 description 30
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 18
- 230000000735 allogeneic effect Effects 0.000 description 17
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 150000003431 steroids Chemical class 0.000 description 15
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 14
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 14
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 14
- 229910002091 carbon monoxide Inorganic materials 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 11
- 229910052711 selenium Inorganic materials 0.000 description 11
- 239000011669 selenium Substances 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 108010071390 Serum Albumin Proteins 0.000 description 9
- 102000007562 Serum Albumin Human genes 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 230000035899 viability Effects 0.000 description 9
- 230000002411 adverse Effects 0.000 description 8
- 239000007640 basal medium Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 8
- 238000010899 nucleation Methods 0.000 description 8
- 230000017423 tissue regeneration Effects 0.000 description 8
- 210000004413 cardiac myocyte Anatomy 0.000 description 7
- 230000010261 cell growth Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000005138 cryopreservation Methods 0.000 description 7
- 210000004748 cultured cell Anatomy 0.000 description 7
- 230000016396 cytokine production Effects 0.000 description 7
- -1 polyethylene Polymers 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- 150000003926 acrylamides Chemical class 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000003761 preservation solution Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001919 adrenal effect Effects 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000017455 cell-cell adhesion Effects 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 210000003098 myoblast Anatomy 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000002437 synoviocyte Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 208000020576 Adrenal disease Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 235000019743 Choline chloride Nutrition 0.000 description 2
- 208000028006 Corneal injury Diseases 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 208000014311 Cushing syndrome Diseases 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 239000004158 L-cystine Substances 0.000 description 2
- 235000019393 L-cystine Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 229930182844 L-isoleucine Natural products 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- 235000019454 L-leucine Nutrition 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 208000006735 Periostitis Diseases 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960003178 choline chloride Drugs 0.000 description 2
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000000959 cryoprotective effect Effects 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 210000002379 periodontal ligament Anatomy 0.000 description 2
- 210000003460 periosteum Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- XLPJNCYCZORXHG-UHFFFAOYSA-N 1-morpholin-4-ylprop-2-en-1-one Chemical compound C=CC(=O)N1CCOCC1 XLPJNCYCZORXHG-UHFFFAOYSA-N 0.000 description 1
- RESPXSHDJQUNTN-UHFFFAOYSA-N 1-piperidin-1-ylprop-2-en-1-one Chemical compound C=CC(=O)N1CCCCC1 RESPXSHDJQUNTN-UHFFFAOYSA-N 0.000 description 1
- WLPAQAXAZQUXBG-UHFFFAOYSA-N 1-pyrrolidin-1-ylprop-2-en-1-one Chemical compound C=CC(=O)N1CCCC1 WLPAQAXAZQUXBG-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- AKVUWTYSNLGBJY-UHFFFAOYSA-N 2-methyl-1-morpholin-4-ylprop-2-en-1-one Chemical compound CC(=C)C(=O)N1CCOCC1 AKVUWTYSNLGBJY-UHFFFAOYSA-N 0.000 description 1
- RASDUGQQSMMINZ-UHFFFAOYSA-N 2-methyl-1-piperidin-1-ylprop-2-en-1-one Chemical compound CC(=C)C(=O)N1CCCCC1 RASDUGQQSMMINZ-UHFFFAOYSA-N 0.000 description 1
- LVCMKNCJDCTPIB-UHFFFAOYSA-N 2-methyl-1-pyrrolidin-1-ylprop-2-en-1-one Chemical compound CC(=C)C(=O)N1CCCC1 LVCMKNCJDCTPIB-UHFFFAOYSA-N 0.000 description 1
- YQIGLEFUZMIVHU-UHFFFAOYSA-N 2-methyl-n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C(C)=C YQIGLEFUZMIVHU-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 206010011039 Corneal perforation Diseases 0.000 description 1
- 206010011044 Corneal scar Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- OXQKEKGBFMQTML-UHFFFAOYSA-N D-glycero-D-gluco-heptitol Natural products OCC(O)C(O)C(O)C(O)C(O)CO OXQKEKGBFMQTML-UHFFFAOYSA-N 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101150022655 HGF gene Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000013875 Heart injury Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 229920002302 Nylon 6,6 Polymers 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 1
- 101710133394 POU domain, class 3, transcription factor 2 Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- OXQKEKGBFMQTML-WAHCGKIUSA-N Perseitol Natural products OC[C@H](O)[C@H](O)C(O)[C@H](O)[C@H](O)CO OXQKEKGBFMQTML-WAHCGKIUSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108010013296 Sericins Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical class C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- DMLAVOWQYNRWNQ-UHFFFAOYSA-N azobenzene Chemical group C1=CC=CC=C1N=NC1=CC=CC=C1 DMLAVOWQYNRWNQ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 108010015046 cell aggregation factors Proteins 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 231100000269 corneal opacity Toxicity 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 238000003851 corona treatment Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940037395 electrolytes Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000012143 endoscopic resection Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000057308 human HGF Human genes 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- KAKALCZDCFZYRN-UHFFFAOYSA-N n-(2-ethoxyethyl)-2-methylprop-2-enamide Chemical compound CCOCCNC(=O)C(C)=C KAKALCZDCFZYRN-UHFFFAOYSA-N 0.000 description 1
- YLQHOUDDHYMERA-UHFFFAOYSA-N n-(2-ethoxyethyl)prop-2-enamide Chemical compound CCOCCNC(=O)C=C YLQHOUDDHYMERA-UHFFFAOYSA-N 0.000 description 1
- KPEKHIHQXHOSRM-UHFFFAOYSA-N n-(oxolan-2-ylmethyl)prop-2-enamide Chemical compound C=CC(=O)NCC1CCCO1 KPEKHIHQXHOSRM-UHFFFAOYSA-N 0.000 description 1
- FIBUWQFQYAAXHD-UHFFFAOYSA-N n-cyclopropyl-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NC1CC1 FIBUWQFQYAAXHD-UHFFFAOYSA-N 0.000 description 1
- LCXIFAOALNZGDO-UHFFFAOYSA-N n-cyclopropylprop-2-enamide Chemical compound C=CC(=O)NC1CC1 LCXIFAOALNZGDO-UHFFFAOYSA-N 0.000 description 1
- ZIWDVJPPVMGJGR-UHFFFAOYSA-N n-ethyl-2-methylprop-2-enamide Chemical compound CCNC(=O)C(C)=C ZIWDVJPPVMGJGR-UHFFFAOYSA-N 0.000 description 1
- SWPMNMYLORDLJE-UHFFFAOYSA-N n-ethylprop-2-enamide Chemical compound CCNC(=O)C=C SWPMNMYLORDLJE-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- OXQKEKGBFMQTML-BIVRFLNRSA-N perseitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO OXQKEKGBFMQTML-BIVRFLNRSA-N 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229940082569 selenite Drugs 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- AAAQKTZKLRYKHR-UHFFFAOYSA-N triphenylmethane Chemical compound C1=CC=CC=C1C(C=1C=CC=CC=1)C1=CC=CC=C1 AAAQKTZKLRYKHR-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
Description
シート状細胞培養物の治療への応用については、火傷などによる皮膚損傷に対する培養表皮シートの利用、角膜損傷に対する角膜上皮シート状細胞培養物の利用、食道ガン内視鏡的切除に対する口腔粘膜シート状細胞培養物の利用などの検討が進められている。
(1)シート状細胞培養物の製造方法であって、
細胞を凍結するステップ、
凍結した細胞を解凍するステップ、および
シート状細胞培養物を形成するステップ
を含む方法。
(2)細胞が自家細胞または他家細胞である、(1)に記載の方法。
(3)細胞が自家細胞である、(1)または(2)に記載の方法。
(4)細胞を解凍するステップの後、細胞を実質的に増殖させずに、シート状細胞培養物を形成する、(1)〜(3)のいずれか一つに記載の方法。
(5)シート状細胞培養物を形成するステップの後に、シート状細胞培養物を回収するステップをさらに含み、細胞を解凍するステップが、シート状細胞培養物を回収するステップの48時間以内前に行われる、(1)〜(4)のいずれか一つに記載の方法。
(6)細胞を凍結するステップの前に、細胞を増殖させるステップを含む、(1)〜(5)のいずれか一つに記載の方法。
(8)細胞が、筋芽細胞、間葉系幹細胞、心筋細胞、線維芽細胞、心臓幹細胞、胚性幹細胞、iPS細胞、滑膜細胞、軟骨細胞、上皮細胞、内皮細胞、肝細胞、膵細胞、腎細胞、副腎細胞、歯根膜細胞、歯肉細胞、骨膜細胞および皮膚細胞からなる群から選択される、(1)〜(7)のいずれか一つに記載の方法。
(9)細胞を凍結するステップと、凍結した細胞を解凍するステップとを含まない方法により製造されたシート状細胞培養物より活性が高いシート状細胞培養物を得る、(1)〜(8)のいずれか一つに記載の方法。
(10)活性が、サイトカイン産生能、生着能、血管誘導能および組織再生能からなる群から選択される、(9)に記載の方法。
(11)サイトカインがHGFおよびVEGFからなる群から選択される、(10)に記載の方法。
(13)(12)に記載のシート状細胞培養物を含む、医薬組成物。
(14)対象において組織の異常に関連する疾患を処置する方法であって、(12)に記載のシート状細胞培養物または(13)に記載の医薬組成物の有効量を、それを必要とする対象に投与することを含む方法。
(15)組織が、心筋、角膜、網膜、食道、皮膚、関節、軟骨、肝臓、膵臓、歯肉、腎臓、甲状腺、骨格筋および中耳からなる群から選択される、(14)に記載の方法。
(16)疾患が、心疾患、角膜疾患、網膜疾患、食道疾患、皮膚疾患、関節疾患、軟骨疾患、肝疾患、膵臓疾患、歯科疾患、腎臓疾患、甲状腺疾患、筋疾患および中耳疾患からなる群から選択される、(14)に記載の方法。
基礎培地は、標準的な組成のまま(例えば、市販されたままの状態で)用いてもよいし、細胞種や細胞条件に応じてその組成を適宜変更してもよい。したがって、本発明に用いる基礎培地は、公知の組成のものに限定されず、1または2以上の成分が追加、除去、増量もしくは減量されたものを含む。
また、本発明の一態様において、基礎培地に含まれるビタミン剤の濃度は、D−パントテン酸カルシウム:4〜12mg/L、塩化コリン:4〜14mg/L、葉酸:0.6〜4mg/L、i−イノシトール:7.2mg/L、ナイアシンアミド:4〜6.1mg/L、リボフラビン:0.0038〜0.4mg/L、チアミン:3.4〜4mg/L、ピリドキシン:2.1〜4mg/Lである。
ここで、「製造工程由来不純物」とは、典型的には、製造各工程に由来する以下に列挙するものが含まれる。すなわち、細胞基材に由来するもの(例えば、宿主細胞由来タンパク質、宿主細胞由来DNA)、細胞培養液に由来するもの(例えば、インデューサー、抗生物質、培地成分)、あるいは細胞培養以降の工程である目的物質の抽出、分離、加工、精製工程に由来するものなどである(例えば、医薬審発第571号参照)。
細胞を「実質的に増殖させない」とは、細胞を計測誤差の範囲を超えて増殖させないことを意味し、細胞が増殖したか否かは、例えば、播種時の細胞数と、細胞培養物形成後の細胞数とを比較することにより評価することができる。本発明において、シート状細胞培養物形成後の細胞数は、典型的には播種時の細胞数の300%以下、好ましくは200%以下、より好ましくは150%以下、さらに好ましくは125%以下、特に好ましくは100%以下である。
本発明の医薬組成物は、本発明のシート状細胞培養物に加えて、種々の追加成分、例えば、薬学的に許容し得る担体や、シート状細胞培養物の生存性、生着性および/または機能などを高める成分、対象疾患の処置に有用な他の有効成分などを含んでいてもよい。かかる追加成分としては、既知の任意のものを使用することができ、当業者はこれらの追加成分について精通している。また、本発明の医薬組成物は、シート状細胞培養物の生存性、生着性および/または機能などを高める成分や、対象疾患の処置に有用な他の有効成分などと併用することができる。一態様において、本発明の医薬組成物は、組織の異常に関連する疾患の処置に用いるためのものである。処置の対象となる組織や疾患は、本発明のシート状細胞培養物について上記したとおりである。
投与頻度は、典型的には1回の処置につき1回であるが、所望の効果が得られない場合には、複数回投与することも可能である。
例1
凍結保存されたヒト骨格筋芽細胞(ヒト骨格筋試料由来)を37℃で解凍し、0.5%血清アルブミンを含む緩衝液を用いて2回洗浄した。5×106〜5×107個の細胞を20%血清含有培地に懸濁し、フラスコに播種した後、2〜3日間培養した。
UpCell(R)(3.5cmディッシュまたは24穴マルチウェル、CellSeed Inc.)に、培養表面が全て覆われる程度の20%血清含有培地を添加し、37℃、5%CO2の環境で3時間〜3日間処理した。処理後、添加した培地は廃棄した。
培養した細胞を回収し、20%血清含有培地に懸濁し、処理済みUpCell(R)に2〜20×105個/cm2の密度で播種し、37℃、5%CO2の環境で約1日間、シート化培養を行った。
5×106〜5×107個のヒト骨格筋芽細胞(ヒト骨格筋試料由来)を20%血清含有培地に懸濁し、フラスコに播種した後、2〜3日間培養した。培養した細胞を回収した後、1〜5×107個/mLの濃度で細胞凍結用保存液(10%DMSO含有基礎培地)に懸濁し、液体窒素タンク内で凍結保存した。
UpCell(R)(3.5cmディッシュまたは24穴マルチウェル、CellSeed Inc.)に、培養表面が全て覆われる程度の20%血清含有培地を添加し、37℃、5%CO2の環境で3時間〜3日間処理を行った。処理後、添加した培地は廃棄した。
凍結保存した骨格筋芽細胞を37℃で解凍し、0.5%血清アルブミンを含む緩衝液を用いて2回洗浄した。洗浄した細胞を20%血清含有培地に懸濁し、処理済みUpCell(R)に2〜20×105個/cm2の密度で播種し、37℃、5%CO2の環境で約1日間、シート化培養を行った。
上記例1または例2におけるシート化培養後に培養上清を全て回収し、ELISA法により培養上清中に産生されたサイトカイン(VEGFおよびHGF)の濃度を測定した(n=3)。測定は、Human VEGF Quantikine ELISA Kit(R&D systems、カタログ番号DVE00)およびRayBio(R) Human HGF ELISA Kit(RayBiotech, Inc.、カタログ番号ELH-HGF-001)を用い、製造者のマニュアルに従って行った。図1に示す結果から、例1および2のいずれの製造方法においても、シート化培養中にVEGFおよびHGFが産生されることがわかる。また、産生量は、例2の製造方法の方が多かった。
例1または例2の方法に従い、UpCell(R)(24穴マルチウェル、CellSeed Inc.)内でシート化したシート状細胞培養物を温度処理により剥離し、HBSS(+)で洗浄した後、2.5%FBS含有MCDB培地を400μLずつ各ウェルに加えて、CO2インキュベーター内で約24時間培養した。培養後、上清を全て回収し、例3と同様にELISA法により培養上清中に産生されたサイトカイン(VEGFおよびHGF)の濃度を測定した。上清を回収したウェルに、再び2.5%FBS含有MCDB培地を400μLずつ添加し、CO2インキュベーター内で48時間培養した。培養後、上清を全て回収し、例3と同様にELISA法によって培養上清中に産生されたサイトカイン(VEGFおよびHGF)の濃度を測定した。図2〜3に示す結果から、例1および2のいずれの製造方法で作製したシート状細胞培養物もVEGFおよびHGFを産生すること、および、産生が96時間もの長期にわたって持続することがわかる。また、産生量は、例2の製造方法で作製したシート状細胞培養物の方が多かった。
凍結保存されたヒト間葉系幹細胞を37℃で解凍し、0.5%血清アルブミンを含む緩衝液を用いて2回洗浄する。5×106〜5×107個の細胞を血清含有培地に懸濁し、フラスコに播種した後、2〜3日間培養する。
UpCell(R)(3.5cmディッシュまたは24穴マルチウェル、CellSeed Inc.)に、培養表面が全て覆われる程度の血清含有培地を添加し、37℃、5%CO2の環境で3時間〜3日間処理を行う。処理後、添加した培地は廃棄する。
培養した細胞を回収し、血清含有培地に懸濁し、処理済みUpCell(R)に2〜20×105個/cm2の密度で播種し、37℃、5%CO2の環境で約1日間シート化培養を行う。
5×106〜3×107個のヒト間葉系幹細胞を血清含有培地に懸濁し、フラスコに播種した後、2〜3日間培養する。培養した細胞を回収した後、1〜5×107個/mLの濃度で細胞凍結用保存液(10%DMSO含有基礎培地)に懸濁し、液体窒素タンク内で凍結保存する。
UpCell(R)(3.5cmディッシュまたは24穴マルチウェル、CellSeed Inc.)に、培養表面が全て覆われる程度の血清含有培地を添加し、37℃、5%CO2の環境で3時間〜3日間処理を行う。処理後、添加した培地は廃棄する。
凍結保存した細胞を37℃で解凍し、0.5%血清アルブミンを含む緩衝液を用いて2回洗浄する。洗浄した細胞を血清含有培地に懸濁し、処理済みUpCell(R)に2〜10×205個/cm2の密度で播種し、37℃、5%CO2の環境で約1日間シート化培養を行う。
凍結保存されたヒト心筋細胞を37℃で解凍し、0.5%血清アルブミンを含む緩衝液を用いて2回洗浄する。5×106〜3×107個の細胞を血清含有培地に懸濁し、フラスコに播種した後、2〜3日間培養する。
UpCell(R)(3.5cmディッシュまたは24穴マルチウェル、CellSeed Inc.)に、培養表面が全て覆われる程度の血清含有培地を添加し、37℃、5%CO2の環境で3時間〜3日間処理を行う。処理後、添加した培地は廃棄する。
培養した細胞を回収し、血清含有培地に懸濁し、処理済みUpCell(R)に2〜20×105個/cm2の密度で播種し、37℃、5%CO2の環境で約1日間シート化培養を行う。
5×106〜3×107個のヒト心筋細胞を血清含有培地に懸濁し、フラスコに播種した後、2〜3日間培養する。培養した細胞を回収した後、1〜5×107個/mLの濃度で細胞凍結用保存液(10%DMSO含有基礎培地)に懸濁し、液体窒素タンク内で凍結保存する。
UpCell(R)(3.5cmディッシュまたは24穴マルチウェル、CellSeed Inc.)に、培養表面が全て覆われる程度の血清含有培地を添加し、37℃、5%CO2の環境で3時間〜3日間処理を行う。処理後、添加した培地は廃棄する。
凍結保存した心筋細胞を37℃で解凍し、0.5%血清アルブミンを含む緩衝液を用いて2回洗浄する。洗浄した細胞を血清含有培地に懸濁し、処理済みUpCell(R)に2〜20×105個/cm2の密度で播種し、37℃、5%CO2の環境で約1日間シート化培養を行う。
1×106〜3×107個のヒト間葉系幹細胞を血清含有培地に懸濁し、フラスコに播種した後、2〜3日間培養した。培養した細胞を回収した後、1〜5×106個/mLの濃度で細胞凍結用保存液(10%DMSO含有基礎培地)に懸濁し、液体窒素タンク内で凍結保存した。
UpCell(R)(48穴マルチウェル、CellSeed Inc.)に、培養表面が全て覆われる程度の血清含有培地を添加し、例1、2、5〜8と同様、37℃、5%CO2、通常の気圧(大気圧)の環境で3時間〜3日間処理を行った。処理後、添加した培地は廃棄した。
凍結保存した細胞を37℃で解凍し、0.5%血清アルブミンを含む緩衝液を用いて2回洗浄した。洗浄した細胞を血清含有培地に懸濁し、処理済みUpCell(R)に2〜20×105個/cm2の密度で播種し、例1、2、5〜8と同様、37℃、5%CO2、通常の気圧(大気圧)の環境で約1日間シート化培養を行った。図4に示すとおり、作製したシート状細胞培養物は均質な白色を呈しており、外観検査上欠陥は認められなかった。
Claims (12)
- HGFおよびVEGFからなる群から選択されるサイトカインの産生能が高いシート状細胞培養物を製造するための方法であって、
凍結した細胞を解凍するステップ、および
解凍した細胞を用いて、培養基材上でシート状細胞培養物を形成するステップ
を含み、凍結した細胞が凍結保護剤の存在下で凍結されたものであり、細胞が骨格筋芽細胞を含み、細胞を解凍するステップとシート状細胞培養物を形成するステップとの間に、細胞を増殖させるステップを含まず、前記産生能が、細胞を解凍するステップとシート状細胞培養物を形成するステップとの間に、細胞を増殖させるステップを含む方法により製造されたシート状細胞培養物の産生能より高い、前記方法。 - 培養基材が血清でコートされている、請求項1に記載の方法。
- シート状細胞培養物を形成するステップが、血清を含む細胞培養液中で行われる、請求項1または2に記載の方法。
- シート状細胞培養物を形成するステップの後に、シート状細胞培養物を回収するステップをさらに含み、シート状細胞培養物を回収するステップが、細胞を解凍するステップから48時間以内に行われる、請求項1〜3のいずれか一項に記載の方法。
- 凍結した細胞を解凍するステップの前に、細胞を凍結するステップを含む、請求項1〜4のいずれか一項に記載の方法。
- 細胞を凍結するステップの前に、細胞を増殖させるステップを含む、請求項5に記載の方法。
- 凍結した細胞を解凍するステップの後、かつ、シート状細胞培養物を形成するステップの前に、細胞を洗浄するステップを含む、請求項1〜6のいずれか一項に記載の方法。
- 細胞が自家細胞である、請求項1〜7のいずれか一項に記載の方法。
- シート状細胞培養物が、組織の異常に関連する疾患を処置するために用いられるものである、請求項1〜8のいずれか一項に記載の方法。
- 組織が、心筋、角膜、網膜、食道、皮膚、関節、軟骨、肝臓、膵臓、歯肉、腎臓、甲状腺、骨格筋および中耳からなる群から選択される、請求項9に記載の方法。
- 疾患が、心疾患、角膜疾患、網膜疾患、食道疾患、皮膚疾患、関節疾患、軟骨疾患、肝疾患、膵臓疾患、歯科疾患、腎臓疾患、甲状腺疾患、筋疾患および中耳疾患からなる群から選択される、請求項9に記載の方法。
- 請求項1〜11のいずれか一項に記載の方法に用いるための、骨格筋芽細胞を含む、凍結保護剤の存在下で凍結した細胞と、培養基材と、血清とを含む組合せ。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014208847A JP5730433B2 (ja) | 2013-05-17 | 2014-10-10 | シート状細胞培養物の製造方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013105204 | 2013-05-17 | ||
JP2013105204 | 2013-05-17 | ||
JP2014208847A JP5730433B2 (ja) | 2013-05-17 | 2014-10-10 | シート状細胞培養物の製造方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014531434A Division JP5634646B1 (ja) | 2013-05-17 | 2014-05-16 | シート状細胞培養物の製造方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014236370A Division JP6599095B2 (ja) | 2013-05-17 | 2014-11-21 | シート状細胞培養物の製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015015963A JP2015015963A (ja) | 2015-01-29 |
JP5730433B2 true JP5730433B2 (ja) | 2015-06-10 |
Family
ID=51898491
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014531434A Active JP5634646B1 (ja) | 2013-05-17 | 2014-05-16 | シート状細胞培養物の製造方法 |
JP2014208847A Active JP5730433B2 (ja) | 2013-05-17 | 2014-10-10 | シート状細胞培養物の製造方法 |
JP2014236370A Active JP6599095B2 (ja) | 2013-05-17 | 2014-11-21 | シート状細胞培養物の製造方法 |
JP2019152514A Withdrawn JP2020000245A (ja) | 2013-05-17 | 2019-08-23 | シート状細胞培養物の製造方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014531434A Active JP5634646B1 (ja) | 2013-05-17 | 2014-05-16 | シート状細胞培養物の製造方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014236370A Active JP6599095B2 (ja) | 2013-05-17 | 2014-11-21 | シート状細胞培養物の製造方法 |
JP2019152514A Withdrawn JP2020000245A (ja) | 2013-05-17 | 2019-08-23 | シート状細胞培養物の製造方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10426802B2 (ja) |
EP (2) | EP2998389B1 (ja) |
JP (4) | JP5634646B1 (ja) |
CN (1) | CN105229145B (ja) |
HK (1) | HK1219502A1 (ja) |
SG (1) | SG11201509441QA (ja) |
WO (1) | WO2014185517A1 (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2998389B1 (en) * | 2013-05-17 | 2018-07-18 | Terumo Kabushiki Kaisha | Production method for sheet-shaped cell culture |
EP3064578B1 (en) | 2014-02-26 | 2021-01-13 | Terumo Kabushiki Kaisha | Method of producing cell population with high target cell purity |
JP6670040B2 (ja) * | 2014-11-18 | 2020-03-18 | テルモ株式会社 | シート状細胞培養物の製造方法 |
JP6948261B2 (ja) * | 2015-07-15 | 2021-10-13 | 国立大学法人大阪大学 | 多能性幹細胞または脂肪組織もしくは骨髄由来の間葉系幹細胞由来の心筋細胞の凍結保存方法 |
JP6884394B2 (ja) * | 2016-01-29 | 2021-06-09 | 学校法人東京女子医科大学 | 間葉系幹細胞を含む細胞シート組成物、及び、それを用いた管腔臓器の治癒方法 |
CA3017871A1 (en) * | 2016-03-18 | 2017-09-21 | Kyoto University | Method for freezing aggregates of pluripotent stem cell-derived cardiomyocytes |
SG11201805456WA (en) | 2016-11-01 | 2019-05-30 | Terumo Corp | Modification method for sheet-shaped cell culture |
EP3530729A4 (en) | 2016-11-25 | 2020-04-15 | Terumo Kabushiki Kaisha | LIQUID FOR PRESERVING LIVING CELLS OR COMPOSITION CONTAINING LIVING CELLS |
WO2018097228A1 (ja) | 2016-11-25 | 2018-05-31 | テルモ株式会社 | 生細胞または生細胞を含む組成物の保存液 |
EP3569693A4 (en) * | 2017-06-05 | 2020-11-18 | Terumo Kabushiki Kaisha | METHOD OF PREPARING A CELL CULTURE |
TWI741263B (zh) | 2018-03-15 | 2021-10-01 | 日商泰爾茂股份有限公司 | 片狀細胞培養物的製造方法 |
TWI745655B (zh) * | 2018-03-15 | 2021-11-11 | 日商泰爾茂股份有限公司 | 片狀細胞培養物的製造方法 |
CN111787959A (zh) * | 2018-07-27 | 2020-10-16 | 国立大学法人长崎大学 | 用于消化道再生的片状细胞培养物 |
CN112638157B (zh) * | 2018-08-30 | 2024-01-09 | 密苏里大学管理机构 | 一种防止样品和细胞外冰直接接触的有效低温保存装置 |
EP3741842A4 (en) * | 2018-09-27 | 2021-04-21 | TERUMO Kabushiki Kaisha | CELL CRYOPRESERVATION METHOD |
EP3739040B1 (en) | 2018-09-27 | 2023-07-05 | Osaka University | Sheeting method for pluripotent stem cell-derived cells |
JP7428657B2 (ja) * | 2018-10-26 | 2024-02-06 | テルモ株式会社 | 標的物質の分離方法および定量方法 |
WO2020092321A1 (en) * | 2018-10-29 | 2020-05-07 | Avery Therapeutics, Inc. | Compositions and methods for cryopreservation and reconstitution of engineered tissues |
AR118008A1 (es) * | 2019-02-07 | 2021-09-08 | Vitricell Sa | Composiciones para criopreservación de un material biológico |
CN110229783A (zh) * | 2019-05-22 | 2019-09-13 | 中国人民解放军总医院 | 一种基于温皿制备干细胞膜片的方法 |
CN110448731A (zh) * | 2019-07-23 | 2019-11-15 | 中国人民解放军总医院 | 温度敏感培养皿制备人心肌球源性干细胞膜性贴片的方法 |
JPWO2021065971A1 (ja) * | 2019-09-30 | 2021-04-08 | ||
WO2021075525A1 (ja) * | 2019-10-17 | 2021-04-22 | テルモ株式会社 | 炎症性疾患を処置するための細胞培養物 |
WO2023136313A1 (ja) * | 2022-01-14 | 2023-07-20 | 国立大学法人大阪大学 | 肝機能障害を処置するための組成物 |
WO2023136312A1 (ja) * | 2022-01-14 | 2023-07-20 | 国立大学法人大阪大学 | 肝機能障害を処置するためのシート状細胞培養物 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5634646B2 (ja) | 1972-11-15 | 1981-08-12 | ||
JPH06104061B2 (ja) | 1989-02-10 | 1994-12-21 | 花王株式会社 | 細胞培養支持体材料 |
US5145770A (en) * | 1990-06-04 | 1992-09-08 | Biosurface Technology, Inc. | Cryopreservation of cultured epithelial sheets |
JP4755368B2 (ja) | 2001-07-24 | 2011-08-24 | 株式会社セルシード | 高密度細胞アレイ用基板、製造法、及びその利用方法 |
EP2266500B1 (en) | 2003-08-01 | 2015-04-01 | CellSeed Inc. | Three-dimensional tissue structure |
JP4338493B2 (ja) * | 2003-10-10 | 2009-10-07 | 株式会社 ジャパン・ティッシュ・エンジニアリング | 細胞培養体の生産方法 |
JP4834802B2 (ja) * | 2004-02-18 | 2011-12-14 | 聡 山上 | ヒト角膜内皮細胞の培養物層積層体及びその作製方法 |
JP2006034200A (ja) * | 2004-07-28 | 2006-02-09 | Pentax Corp | 細胞培養担体、細胞培養担体の製造方法および細胞培養方法 |
JP4161106B2 (ja) | 2004-09-30 | 2008-10-08 | 独立行政法人科学技術振興機構 | 細胞剥離剤及び細胞シート剥離方法 |
JP5103626B2 (ja) * | 2005-01-27 | 2012-12-19 | 財団法人ヒューマンサイエンス振興財団 | 間葉系幹細胞を含む細胞シート |
ES2693609T3 (es) * | 2005-02-28 | 2018-12-12 | Cellseed Inc. | Lámina de células cultivadas, método para su producción y método para su aplicación |
JP2008022715A (ja) * | 2006-07-18 | 2008-02-07 | Nipro Corp | 細胞シート培養方法及び細胞培養容器 |
JP2008136420A (ja) * | 2006-12-01 | 2008-06-19 | Terumo Corp | 医療用培養細胞の調製方法 |
JP2009082005A (ja) * | 2007-09-27 | 2009-04-23 | Dainippon Printing Co Ltd | 収縮が抑制された細胞シートの製造方法 |
JP2009219376A (ja) * | 2008-03-13 | 2009-10-01 | Terumo Corp | 医療用細胞の保護用液 |
JP5378743B2 (ja) * | 2008-09-30 | 2013-12-25 | テルモ株式会社 | 医療用細胞シートの製造方法 |
JP5436905B2 (ja) * | 2009-03-26 | 2014-03-05 | テルモ株式会社 | シート状細胞培養物の製造方法 |
JPWO2011058813A1 (ja) * | 2009-11-13 | 2013-03-28 | 芳樹 澤 | 心筋再生用細胞シート、製造方法及びその利用方法 |
JP5702060B2 (ja) * | 2009-12-01 | 2015-04-15 | テルモ株式会社 | 単離されたシート状細胞培養物の製造方法 |
JP5737860B2 (ja) * | 2010-04-30 | 2015-06-17 | テルモ株式会社 | ゲル状細胞組成物およびその製造方法 |
EP2682134A4 (en) * | 2011-02-28 | 2015-11-04 | Univ Tokyo Womens Medical | CELLULAR SHEET PRODUCING CYTOKINES AND METHOD FOR USE THEREOF |
JP2012235731A (ja) | 2011-05-11 | 2012-12-06 | Tokyo Women's Medical College | 骨格筋芽細胞の心筋細胞への分化方法、心筋移植材の製造方法および心筋移植材 |
EP2998389B1 (en) * | 2013-05-17 | 2018-07-18 | Terumo Kabushiki Kaisha | Production method for sheet-shaped cell culture |
-
2014
- 2014-05-16 EP EP14797732.6A patent/EP2998389B1/en active Active
- 2014-05-16 JP JP2014531434A patent/JP5634646B1/ja active Active
- 2014-05-16 CN CN201480028775.8A patent/CN105229145B/zh active Active
- 2014-05-16 SG SG11201509441QA patent/SG11201509441QA/en unknown
- 2014-05-16 WO PCT/JP2014/063058 patent/WO2014185517A1/ja active Application Filing
- 2014-05-16 EP EP18176126.3A patent/EP3388510A1/en active Pending
- 2014-10-10 JP JP2014208847A patent/JP5730433B2/ja active Active
- 2014-11-21 JP JP2014236370A patent/JP6599095B2/ja active Active
-
2015
- 2015-11-17 US US14/943,161 patent/US10426802B2/en active Active
-
2016
- 2016-06-28 HK HK16107482.2A patent/HK1219502A1/zh unknown
-
2019
- 2019-08-23 JP JP2019152514A patent/JP2020000245A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP6599095B2 (ja) | 2019-10-30 |
EP3388510A1 (en) | 2018-10-17 |
JP5634646B1 (ja) | 2014-12-03 |
JP2015015963A (ja) | 2015-01-29 |
SG11201509441QA (en) | 2015-12-30 |
HK1219502A1 (zh) | 2017-04-07 |
US10426802B2 (en) | 2019-10-01 |
JP2020000245A (ja) | 2020-01-09 |
WO2014185517A1 (ja) | 2014-11-20 |
JP2015077135A (ja) | 2015-04-23 |
CN105229145A (zh) | 2016-01-06 |
EP2998389B1 (en) | 2018-07-18 |
EP2998389A4 (en) | 2016-11-30 |
CN105229145B (zh) | 2020-08-28 |
EP2998389A1 (en) | 2016-03-23 |
JPWO2014185517A1 (ja) | 2017-02-23 |
US20160067284A1 (en) | 2016-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5730433B2 (ja) | シート状細胞培養物の製造方法 | |
JP5667357B2 (ja) | シート状細胞培養物の製造方法 | |
JP5702060B2 (ja) | 単離されたシート状細胞培養物の製造方法 | |
JPWO2017010544A1 (ja) | 多能性幹細胞または脂肪組織もしくは骨髄由来の間葉系幹細胞由来の心筋細胞の凍結保存方法 | |
JP6670040B2 (ja) | シート状細胞培養物の製造方法 | |
JP5727665B2 (ja) | シート状細胞培養物の製造方法 | |
WO2018168983A1 (ja) | シート状細胞培養物の製造方法 | |
JP6130868B2 (ja) | 単離されたシート状細胞培養物の製造方法 | |
JP7262443B2 (ja) | 貫通構造を有するシート状細胞培養物 | |
JP5893786B2 (ja) | シート状細胞培養物の製造方法 | |
JP7307408B2 (ja) | シート状細胞培養物の製造方法 | |
JP2019154363A (ja) | 医療用細胞培養物 | |
JP2021052661A (ja) | 多能性幹細胞を含む凍結保存細胞の希釈用緩衝液 | |
WO2019177135A1 (ja) | シート状細胞培養物の製造方法 | |
US20200390936A1 (en) | Method for cryopreserving cells | |
WO2020067434A1 (ja) | 細胞の凍結保存方法 | |
WO2021065971A1 (ja) | 凍結保存細胞の希釈用緩衝液 | |
JP6490738B2 (ja) | シート状細胞培養物の製造方法 | |
JP6140322B2 (ja) | シート状細胞培養物の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141126 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141126 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20141126 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20141209 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150113 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150305 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150325 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150407 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5730433 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |